Please check your internet connection and try again.
# Urimax (Tamsulosin)
## Overview
Tamsulosin is a selective α1-adrenoceptor antagonist that reduces smooth muscle tone in the prostate and bladder neck. It exhibits higher selectivity for the α1A and α1D receptors found in the prostate compared to vascular α1B receptors.
## Primary Indications
* Signs and symptoms of Benign Prostatic Hyperplasia (BPH).
* Off-label: Medical expulsive therapy (MET) for distal ureteral stones.
* Off-label: Urinary retention (as an adjunct to catheterization).
## Adult Dosing
* **BPH:** 0.4 mg orally once daily, taken 30 minutes after the same meal each day.
* **Maximum Dose:** 0.8 mg daily. If no response after 2–4 weeks at 0.4 mg, the dose may be increased to 0.8 mg.
## Pediatric Dosing
* **Not established.** Safety and efficacy have not been established in the pediatric population. It is generally not indicated for use in children.
## Dose Adjustments
* **Renal Impairment:** No dosage adjustment indicated; however, use with caution in patients with severe impairment (CrCl <10 mL/min).
* **Hepatic Impairment:** No dosage adjustment for mild/moderate impairment. Not recommended in severe hepatic impairment.
* **CYP3A4/2D6 Inhibitors:** Avoid or exercise caution when co-administered with potent inhibitors.
## Contraindications
* Hypersensitivity to tamsulosin or any component of the formulation.
* History of angioedema or severe allergic reactions to sulfonamides (potential cross-reactivity, though clinical evidence is debated).
## Adverse Effects
* **Common:** Dizziness, headache, abnormal ejaculation (retrograde), rhinitis, asthenia, orthostatic hypotension.
* **Serious:** Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery, syncope, severe hypotension.
## Key Drug Interactions
* **Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin):** Increase tamsulosin exposure; monitor for hypotension.
* **Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine):** May increase plasma concentrations of tamsulosin.
* **PDE5 inhibitors (e.g., sildenafil, tadalafil):** Potential for additive hypotensive effects; initiate at the lowest dose of PDE5 inhibitor.
## Monitoring
* Baseline and periodic blood pressure (especially orthostatic).
* Symptom relief (AUA Symptom Score) to assess efficacy.
* Prostate cancer screening (PSA) prior to initiation to rule out malignancy.
* Ophthalmologic consultation prior to cataract/glaucoma surgery.
## Clinical Pearls
* **Administration:** Must be taken 30 minutes after the same meal every day to ensure consistent bioavailability; taking on an empty stomach increases peak plasma concentrations and risk of orthostatic hypotension.
* **Surgery:** If the patient is scheduled for cataract surgery, inform the surgeon of current or past tamsulosin use to prevent IFIS complications.
* **Syncope:** Advise patients to rise slowly from a sitting/lying position, especially when starting therapy or increasing the dose.
* **Capsule Integrity:** Do not crush, chew, or open the capsules, as this bypasses the extended-release mechanism.
***
*Disclaimer: This information is for educational purposes only. Always consult current prescribing information, institutional protocols, and clinical guidelines before prescribing or administering medication.*
